Tonstad Serena
Ullevål University Hospital, Department of Preventive Cardiology N-0407 Oslo, Norway.
Expert Rev Neurother. 2007 Feb;7(2):121-7. doi: 10.1586/14737175.7.2.121.
Varenicline is a selective alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist and the first non-nicotine-containing medication developed with the sole purpose of treating nicotine addiction. To date, four published clinical trials have demonstrated the efficacy and safety of varenicline for smoking cessation in healthy adults who were ready to make a quit attempt. One additional trial found that extended use of varenicline effectively reduced relapse to smoking. One trial to date published as a poster documented the 1-year safety of the drug. Varenicline was more efficacious than bupropion 24 weeks after randomization to a 12-week treatment course and 1 year after randomization in an identical trial. It has no contraindications except hypersensitivity and is well tolerated. This article reviews the available information on varenicline and discusses its clinical use.
伐尼克兰是一种选择性α(4)β(2)烟碱型乙酰胆碱受体部分激动剂，是首个专门为治疗尼古丁成瘾而研发的不含尼古丁的药物。迄今为止，四项已发表的临床试验证明了伐尼克兰对准备尝试戒烟的健康成年人戒烟的有效性和安全性。另一项试验发现，延长伐尼克兰的使用能有效减少复吸。迄今为止，有一项以海报形式发表的试验记录了该药物的1年安全性。在一项为期12周治疗疗程的试验中，随机分组24周后以及在相同试验中随机分组1年后，伐尼克兰比安非他酮更有效。除过敏外，它没有禁忌证，耐受性良好。本文综述了有关伐尼克兰的现有信息并讨论了其临床应用。
